Treatment of COPD with long-acting bronchodilators: association between early and longer-term clinically important improvement
CF Vogelmeier, IP Naya, F Maltais… - … Journal of Chronic …, 2021 - Taylor & Francis
Introduction This post hoc analysis of the “Early MAXimization of bronchodilation for
improving COPD stability”(EMAX) trial investigated whether patients achieving early …
improving COPD stability”(EMAX) trial investigated whether patients achieving early …
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the …
F Maltais, L Bjermer, EM Kerwin, PW Jones… - Respiratory …, 2019 - Springer
Background Prospective evidence is lacking regarding incremental benefits of long-acting
dual-versus mono-bronchodilation in improving symptoms and preventing short-term …
dual-versus mono-bronchodilation in improving symptoms and preventing short-term …
Early Clinically Important Improvement (ECII) and exacerbation outcomes in COPD patients
K Kostikas, AJ Mackay, CF Vogelmeier… - … Journal of Chronic …, 2020 - Taylor & Francis
Background Chronic obstructive pulmonary disease (COPD) exacerbations are difficult
outcomes to measure in clinical trials. It would be valuable to be able to predict which …
outcomes to measure in clinical trials. It would be valuable to be able to predict which …
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial
EM Kerwin, IH Boucot, CF Vogelmeier… - Therapeutic …, 2020 - journals.sagepub.com
Background: In chronic obstructive pulmonary disease (COPD), both the time needed for
patients to gain symptom improvement with long-acting bronchodilator therapy and whether …
patients to gain symptom improvement with long-acting bronchodilator therapy and whether …
Dual bronchodilator therapy as first-line treatment in maintenance-naïve patients with symptomatic COPD: a pre-specified analysis of the EMAX trial
L Bjermer, IH Boucot, F Maltais, EM Kerwin… - … Journal of Chronic …, 2021 - Taylor & Francis
Introduction Limited prospective evidence is available to guide selection of first-line
maintenance therapy in patients with COPD. This pre-specified analysis of the EMAX trial …
maintenance therapy in patients with COPD. This pre-specified analysis of the EMAX trial …
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
Background Endpoints that evaluate deterioration rather than improvement of disease may
have clinical utility in COPD. In this analysis, we compared the effects of different …
have clinical utility in COPD. In this analysis, we compared the effects of different …
[HTML][HTML] Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD
M Cazzola, KM Beeh, D Price, N Roche - Pulmonary pharmacology & …, 2015 - Elsevier
The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary
disease (COPD) vary in their pharmacological class (β 2-adrenergic agonist or …
disease (COPD) vary in their pharmacological class (β 2-adrenergic agonist or …
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post …
IP Naya, L Tombs, DA Lipson, C Compton - Advances in Therapy, 2018 - Springer
Introduction Assessing clinically important measures of disease progression is essential for
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
CF Vogelmeier, EM Kerwin… - Therapeutic …, 2020 - journals.sagepub.com
Rationale: Symptom relief is a key treatment goal in patients with chronic obstructive
pulmonary disease (COPD). However, there are limited data available on the response to …
pulmonary disease (COPD). However, there are limited data available on the response to …
Effect of timing of bronchodilator therapy initiation on exacerbations in patients with chronic obstructive pulmonary disease: a retrospective cohort study
H Yamada, I Matsumoto, N Makita, Y Arita… - Respiratory …, 2022 - Springer
Background The benefit of prompt vs delayed treatment initiation with inhaled long-acting
bronchodilators in reducing exacerbations in chronic obstructive pulmonary disease (COPD) …
bronchodilators in reducing exacerbations in chronic obstructive pulmonary disease (COPD) …